Fennec Pharmaceuticals Inc.
PEDMARK
cisplatin-induced hearing loss
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews PEDMARK for cisplatin-induced hearing loss around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“The management team will host one-on-one investor meetings at the annual Piper Sandler Spring Biopharma Symposium being held April 15–April 16, 2026 at the Convene One Boston Place.”